MXCT
MaxCyte Inc

438
Mkt Cap
$156.81M
Volume
651,529.00
52W High
$5.20
52W Low
$1.26
PE Ratio
-3.47
MXCT Fundamentals
Price
$1.49
Prev Close
$1.47
Open
$1.47
50D MA
$1.60
Beta
1.45
Avg. Volume
926,844.05
EPS (Annual)
-$0.3916
P/B
0.88
Rev/Employee
$338,833.33
Loading...
Loading...
News
all
press releases
MaxCyte, Inc. (NASDAQ:MXCT) Given Consensus Rating of "Hold" by Brokerages
Shares of MaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) have been assigned an average rating of "Hold" from the five ratings firms that are covering the firm, MarketBeat reports. One research analyst...
MarketBeat·19h ago
News Placeholder
More News
News Placeholder
Mirabella Financial Services LLP Has $14.39 Million Stock Position in MaxCyte, Inc. $MXCT
Mirabella Financial Services LLP raised its position in MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 78.4% during the second quarter, according to the company in its most recent disclosure with the...
MarketBeat·13d ago
News Placeholder
MaxCyte (NASDAQ:MXCT) Upgraded to Hold at Wall Street Zen
Wall Street Zen upgraded shares of MaxCyte from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·25d ago
News Placeholder
FY2025 EPS Estimates for MaxCyte Boosted by William Blair
MaxCyte, Inc. (NASDAQ:MXCT - Free Report) - Stock analysts at William Blair upped their FY2025 earnings per share estimates for MaxCyte in a report released on Thursday, November 13th. William Blair...
MarketBeat·1mo ago
News Placeholder
MaxCyte (NASDAQ:MXCT) Announces Quarterly Earnings Results
MaxCyte (NASDAQ:MXCT - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus...
MarketBeat·1mo ago
News Placeholder
Insights into MaxCyte's Upcoming Earnings
read more...
Benzinga·1mo ago
News Placeholder
Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Beats Revenue Estimates
Avidity Biosciences (RNA) delivered earnings and revenue surprises of -20.95% and +399.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Beat Estimates
ANI (ANIP) delivered earnings and revenue surprises of +17.24% and +7.81%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates
MaxCyte (MXCT) delivered earnings and revenue surprises of -20.00% and -14.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
chainwire·7mo ago
<
1
2
...
>

Latest MXCT News

View

Advertisement|Remove ads.

Advertisement|Remove ads.